Download MendeleyIminosugar C-Glycosides Work as Pharmacological Chaperones of NAGLU, a Glycosidase Involved in MPS IIIB Rare Disease*.
Zhu, S., Jagadeesh, Y., Tran, A.T., Imaeda, S., Boraston, A., Alonzi, D.S., Poveda, A., Zhang, Y., Desire, J., Charollais-Thoenig, J., Demotz, S., Kato, A., Butters, T.D., Jimenez-Barbero, J., Sollogoub, M., Bleriot, Y.(2021) Chemistry 27: 11291-11297
- PubMed: 34106504
- DOI: https://doi.org/10.1002/chem.202101408
- Primary Citation of Related Structures:
7MFK, 7MFL - PubMed Abstract:
Mucopolysaccharidosis type IIIB is a devastating neurological disease caused by a lack of the lysosomal enzyme, α-N-acetylglucosaminidase (NAGLU), leading to a toxic accumulation of heparan sulfate. Herein we explored a pharmacological chaperone approach to enhance the residual activity of NAGLU in patient fibroblasts. Capitalizing on the three-dimensional structures of two modest homoiminosugar-based NAGLU inhibitors in complex with bacterial homolog of NAGLU, CpGH89, we have synthesized a library of 17 iminosugar C-glycosides mimicking N-acetyl-D-glucosamine and bearing various pseudo-anomeric substituents of both α- and β-configuration. Elaboration of the aglycon moiety results in low micromolar selective inhibitors of human recombinant NAGLU, but surprisingly it is the non-functionalized and wrongly configured β-homoiminosugar that was proved to act as the most promising pharmacological chaperone, promoting a 2.4 fold activity enhancement of mutant NAGLU at its optimal concentration.
Organizational Affiliation:
Sorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, UMR 8232, 4 place Jussieu, 75005, Paris, France.
